Company
| Name | Cyto-Facto Inc. |
|---|---|
| Representative | Shin Kawamata, MD, PhD, CEO |
| Location | Shimin Byoin Mae Bldg 3F, 2-1-11, Minatojima-minamimachi, Chuo-ku, Kobe, Japan |
| Establishment | October 18th, 2022 |
| Employees | 64 (as of June 1st, 2024) |
History
The Cell Therapy Development Center (RDC), the predecessor of Cyto-Facto, has accumulated expertise and achievements in GMP-compliant manufacturing, as Asia's first site to produce the world’s first cell and gene product, CAR-T cell therapy, specifically for the commercial production of Kymriah intravenous infusion.
Building on that experience, Cyto-Facto has also started accepting orders for the manufacturing of investigational products using mesenchymal stem cells (MSC).
| 2014 |
The Cell Therapy Development Center (RDC) begins the CAR-T CMO project. Technology transfer for CAR-T manufacturing (Kimriah intravenous infusion) conducted by Novartis. |
|---|---|
| 2017 |
Completion and operational launch of cell manufacturing facilities (CPC1-4) on the 6th floor of the Kobe Eye Center. |
| 2018 |
Initiation of investigational product manufacturing for Kimriah intravenous infusion. |
| 2020 |
Approval for manufacturing and sales of regenerative medicine products (PMDA). Commencement of commercial manufacturing for Kimriah intravenous infusion. |
| 2021 |
First shipment of Kimriah intravenous infusion. Technology transfer for MSC manufacturing (FF-31501) conducted by Fujifilm/Fujifilm Toyama Chemical. |
| 2022 |
Completion and operational launch of cell manufacturing facilities (CPC) on the 5th floor of KCMI. |
| 2023 |
Cyto-Facto Inc. established as a spin-out from FBRI. Initiation of investigational product manufacturing for FF-31501. |
| 2024 |
Planned start of process development for CAR-T and MSC manufacturing for multiple clients. |